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Abstract
Background: The optimal strategy for weaning very preterm infants from nasal continuous positive airway pressure
(NCPAP) is unclear. Reported strategies include weaning NCPAP to a predefined pressure then trialling stopping
completely (abrupt wean); alternate periods of increased time off NCPAP whilst reducing time on until the infant is
completely weaned (gradual wean); and using high flow nasal cannula (HFNC) to assist the weaning process. The
aim of this study was to determine the optimal weaning from NCPAP strategy for very preterm infants.
Methods: A pilot single centre, factorial design, 4-arm randomised controlled trial. Sixty infants born <30 weeks
gestation meeting stability criteria on NCPAP were randomly allocated to one of four groups. Group 1: abrupt wean
with HFNC; Group 2: abrupt wean without HFNC; Group 3: gradual wean with HFNC; Group 4: gradual wean
without HFNC. The primary outcomes were duration of respiratory support, chronic lung disease, length of hospital
stay and time to full suck feeds.
Results: The primary outcome measures were not significantly different between groups. Group 1 had a significant
reduction in duration of NCPAP (group 1: median 1 day; group 2: 24 days; group 3: 15 days; group 4: 24 days; p = 0.002)
and earlier corrected gestational age off NCPAP. There was a significant difference in rate of parental withdrawal from
the study, with group 2 having the highest rate. Group 3 had a significantly increased duration on HFNC
compared to group 1.
Conclusions: Use of high flow nasal cannula may be effective at weaning infants from NCPAP but did not
reduce duration of respiratory support or time to full suck feeds. Abrupt wean without the use of HFNC was
associated with an increased rate of withdrawal by parent request.
Trial registration: This study is registered at the Australian New Zealand Clinical Trials Registry
(www.anzctr.org.au/). (Registration Number = ACTRN12610001003066).
Keywords: High flow nasal cannula, Continuous positive airway pressure, Ventilator weaning, Infant, Premature
Background
Nasal continuous positive airway pressure (NCPAP) is
effective at preventing intubation in preterm infants [1,
2] and preventing extubation failure in infants after
mechanical ventilation [3]. Subsequently, various strat-
egies have been trialled for the withdrawal of NCPAP in
preterm infants [4]. Trials have compared a gradual
reduction of NCPAP pressure versus increasing duration
of time off; [5, 6] and also initially weaning pressure to
4-6cmH2O and then comparing attempts to take infants
off NCPAP (‘abrupt weaning’) versus increasing duration
of time off (‘gradual weaning’), with or without the
addition of low flow nasal cannula [7]. This later study
reported a decreased length of stay for babies rando-
mised to a weaning strategy where NCPAP is simply
stopped when infants met predefined stability criteria.
However, NCPAP has side effects including gaseous dis-
tension of the bowel, nasal trauma, and nasal deformity if
NCPAP use is prolonged [8]. Heated, humidified high flow
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nasal cannula (HFNC) using flow rates greater than 1 L/
min [9] are being used as an alternative to NCPAP. Sur-
veys in Australia and the United Kingdom document its
widespread use as an alternative to NCPAP, weaning off
CPAP and post extubation [10, 11]. Trials comparing use
of HFNC versus NCPAP for facilitating extubation in pre-
term infants report similar efficacy for prevention of extu-
bation failure [12, 13] and reduced nasal trauma with
HFNC [14]. Previous research reported that use of HFNC
in preterm infants for weaning from NCPAP is associated
with an increased exposure to oxygen and longer duration
of respiratory support. [15] However, HFNC flow was re-
stricted to 2 L/min and infants weaned from NCPAP were
on a relatively high fraction inspired oxygen (FiO2 ≤ 0.3)
so may have had relatively severe lung disease.
This is a pilot study designed to inform the optimal
comparisons for a larger trial. The primary aim of a lar-
ger trial will be to determine the optimal method for
weaning infants born <30 weeks gestation from NCPAP
to reduce duration of respiratory support and time to
full suck feeds. The secondary aims are to determine the
efficacy of abrupt versus gradual weaning from NCPAP;
and the efficacy of use of HFNC versus no HFNC for
weaning infants from NCPAP.
Methods
Study population and study design
This was a pilot, single-centre, prospective randomised
control trial investigating the optimal method of wean-
ing preterm infants from NCPAP using a 2 X 2 factorial
design (Fig. 1) (ACTRN12610001003066). Informed par-
ental consent was obtained before enrolment. Ethics ap-
proval for the study was obtained from the Sydney
South West Area Health Service Human Ethics and Re-
search Committee (X10-0262).
All infants born <30 weeks gestation on NCPAP at Royal
Prince Alfred Hospital between October 2010 and June
2012 were eligible for inclusion in the study if they met
the following criteria: 1) clinically stable on ≤5 cm H2O
NCPAP (mouth closed); or 2) clinically stable on NCPAP
(any level) but tolerating 6 h with mouth open; or 3) clinic-
ally stable on NCPAP (any level) and tolerating 6 h off
NCPAP. Mouth closure was achieved by use of a chin
strap or a pacifier and targeted to the infant’s work of
breathing. A ≥6 FG gastric tube was used to avoid gastric
over distension with air. Infants were excluded from study
participation for the following reasons: 1) current infection
with positive blood or CSF culture within previous 48 h; 2)
major congenital or chromosomal abnormality; or 3) se-
vere neurologic insult or neuromuscular disease.
Intervention
Once informed parental consent was obtained, eligibility
criteria [7] were confirmed by completing a randomisation
form. Infants were randomised using sequentially num-
bered, opaque, sealed envelopes prepared in blocks of 4 to
8. The order of randomisation was allocated using a ran-
dom number generator. Infants were randomised to one
of four groups (Fig. 1):
Group 1: Abrupt wean from NCPAP to HFNC. Infant
was taken off NCPAP completely and put on HFNC
starting at 6 L/min.
Group 2: Abrupt wean from NCPAP without HFNC.
Infant taken off NCPAP and received crib air or up to
25 % oxygen or low flow nasal cannula oxygen if
required (≤1 L/min).
Group 3: Gradual wean from NCPAP to HFNC.
Infants gradually weaned off NCPAP by alternately
placing onto HFNC for increasing lengths of time. As a
guide, infants started at 6 h NCPAP and 1 h HFNC.
Time on HFNC was increased by 1 h if stable, for each
alternative period until 6 h on HFNC. Then NCPAP
reduced by 1 h each alternative period until on
continuous HFNC.
Group 4: Gradual wean from NCPAP without HFNC.
Infants gradually weaned off NCPAP by placing in crib
air or up to 25 % oxygen or low flow nasal cannula
oxygen if required (≤1 L/min) for increasing lengths of
time. Infants started at 6 h NCPAP and 1 h off, with
time off increased by 1 h if stable, each alternative
period until off NCPAP. This was standard practice
at RPA. Infants in groups 1 and 2 were placed back
on NCPAP for at least 48 h or until stability criteria
achieved if they met 2 or more failure criteria
(derived from a previous trial [7]).
Stability criteria
 NCPAP (mouth closed) ≤5 cm H2O,
 FiO2 ≤ 0.25 and not increasing,
 Respiratory rate ≤60 per minute,
 No significant chest recession,
 Less than 3 episodes of apnea, bradycardia, oxygen
desaturation (<80 % for >20 s) in 1 h for the
previous 12 h,
 Average oxygen saturation (SpO2) >86 % most of the
time or PaO2 > 45 mmHg, and
 Not currently treated for patent ductus arteriosus
(PDA) or sepsis.
Failure criteria
 Increase work of breathing (intercostal recession and
use of accessory muscles) with respiratory rate >75
per minute,
 Increased apnea and/or bradycardia and/or
desaturations >2 in 1 h for the previous 6-h period,
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 FiO2 requirement >0.25 to maintain SpO2 > 86 %
and/or PaO2 > 45 mmHg,
 pH <7.2,
 PaCO2 > 65 mm Hg, or
 Apnea or bradycardia requiring resuscitation.
Study devices
For HFNC, nasal cannula with outer diameter 2.4 mm
(Fisher and Paykel Healthcare, Auckland, New Zealand)
was connected to a circuit (Infant Oxygen Therapy Sys-
tem RT329, Fisher and Paykel) and humidifier (MR850,
Fisher and Paykel). Flow rates were between 2 and 6 L/
min. For NCPAP, short binasal prongs were used in con-
junction with an underwater bubble NCPAP device
(Fisher and Paykel) and flow rate was set ≥1 L/min
above the ‘bubbling point’.
Study outcomes
Primary outcomes were 1) chronic lung disease (CLD)
defined as respiratory support or oxygen at 36 weeks’
corrected gestational age (cGA); 2) days respiratory sup-
port (NCPAP or HFNC or oxygen); 3) days of hospital
stay; and 4) days to achieve full suck feeds. Secondary
outcomes were 1) days NCPAP; 2) cGA off NCPAP; 3)
HFNC days (from commencement); 4) pressure support
days (NCPAP or HFNC); 5) cGA off pressure support; 6)
cGA off respiratory support; 6) postnatal growth failure
(weight <10th percentile) at 36 weeks cGA; 7) weight at
36 weeks’ cGA; 8) adverse events including grade 2
apnea (required intermittent positive pressure ventila-
tion (IPPV)), pulmonary air leak, necrotising enterocoli-
tis (NEC), PDA treatment, late onset sepsis; and 9) nasal
injury. Outcomes are reported from time of randomisa-
tion unless otherwise specified.
Statistical analysis
All data were analysed using SPSS (IBM SPSS Statistics
version 21.0) using 2-sided tests and intention to treat
(ITT) analysis. The data for infants withdrawn from
treatment is reported in group of assignment. Primary
analysis is reported for the 4 groups. In view of the fac-
torial design, a secondary analysis is reported for com-
bined groups: abrupt wean versus gradual wean; and
HFNC versus no HFNC. All analyses were prespecified
in the protocol. Dichotomous data are reported as me-
dians and interquartile range (IQR) or means and stand-
ard deviation (sd) where appropriate. As a substantial
proportion of time-related data had skewed distributions,
non-parametric statistics were predominately reported.
Statistical significance was assessed using ANOVA and
Student t-test for differences in means of parametric data,
and independent sample Kruskal-Wallis and Mann–
Whitney U tests for non-parametric data. Dichotomous
data were analysed using Pearson chi [2] or Fisher exact test
where appropriate. Statistical significance was assumed at
the p ≤ 0.05 level for primary outcomes and p ≤ 0.01 for
Fig. 1 Flow Chart of the study showing patient allocation and follow up
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secondary outcomes. Sample size calculation was not per-
formed as this was a pilot study.
Results
Ninety infants were born <30 weeks gestational age
October 2010 and June 2012. Sixty eligible infants
were enrolled and randomised, 15 to each group. Rea-
sons for non-enrolment are reported in Fig. 1. All infants
received the allocated treatment and were analysed by
intention to treat. The groups were well balanced for peri-
natal and clinical characteristics after randomisation
(Table 1). Infants randomised had a mean gestation
27.5 weeks (range 24.0–29.9) and birth weight 989 g
(574–1617). They were aged 28 days (range 2–76) with
mean postmenstrual age 31 weeks (27–37) and weight
1237 g (662–1890) and were similar between groups. In-
fants were on mean FiO2 0.21 (range 21–23), pressure 5
cmH20 (5–5), on NCPAP for 19 h (5–24) and tolerated
5 h (0–15) off NCPAP and were similar between groups.
Seven infants were withdrawn at parent request from
the allocated treatment, 6 (40 %) infants who were allo-
cated to group 2 (abrupt NCPAP wean without HFNC)
and 1 infant allocated to group 3 (gradual NCPAP wean
with HFNC). The difference in withdrawal rate was sta-
tistically significant (ANOVA p = 0.01). The reason for
withdrawal of all infants was dissatisfaction with wean-
ing method. Infant outcomes are reported for all infants
in an intention to treat analysis.
Four-group comparison
No significant difference was found between groups for
primary outcomes including CLD, respiratory support
days, days to full suck feeds and days of hospital stay from
randomisation (Table 2). There was a significant difference
in duration of NCPAP between groups with group 1
(abrupt wean with HFNC) having a median 1 day on
NCPAP, compared to group 2 with 24 days, group 3 with
15 days and group 4 with 24 days (ANOVA p = 0.002).
Group 1 had a significantly reduced duration of NCPAP
and cGA off NCPAP compared to groups 2–4 combined
(Fisher exact test p < 0.01). There was a significant differ-
ence between groups 1 and 3 in days HFNC from start of
treatment (median 15 days versus 30 days; p = 0.004).
There were no significant differences between groups in
days of pressure support, cGA off pressure support, cGA
off respiratory support, cGA at full suck feeds, cGA at hos-
pital discharge and days of caffeine use. Incidences of ad-
verse events (grade 2 apnea, NEC, PDA treatment, ROP
and laser treatment) after randomisation were not
Table 1 Baseline perinatal and clinical characteristics of groups at randomisation (n (%) or median (IQR) unless specified)
Group 1 Group 2 Group 3 Group 4 p
(n = 15) n = 15 n = 15 n = 15
Mean gestation (sd) 27.7 (1.5) 27.1 (1.8) 27.5 (1.3) 27.7 (1.1) 0.6
Mean birthweight - g (sd) 1027 (229) 945 (211) 975 (280) 1010 (282) 0.8
Complete corticosteroids 12 (80 %) 9 (60 %) 8 (53 %) 13 (87 %) 0.1
Mother in labour 7 (47 %) 6 (40 %) 7 (47 %) 6 (40 %) 0.9
Caesarean 14 (93 %) 11 (73 %) 12 (80 %) 12 (80 %) 0.5
Chorioamnionitis 6 (40 %) 4 (27 %) 4 (27 %) 4 (27 %) 0.6
Male 4 (26 %) 5 (33 %) 9 (60 %) 7 (47 %) 0.3
Mechanical ventilation 15 (100 %) 14 (93 %) 14 (93 %) 13 (87 %) 0.5
Surfactant 14 (93 %) 13 (87 %) 14 (93 %) 14 (93 %) 0.9
Diuretics 5 (33 %) 2 (13 %) 4 (27 %) 2 (13 %) 0.4
Grade 2 apnea (required IPPV) 1 (7 %) 2 (13 %) 3 (20 %) 2 (13 %) 0.8
Caffeine 15 (100 %) 15 (100 %) 15 (100 %) 15 (100 %)
Full enteral feeds 10 (67 %) 10 (67 %) 9 (60 %) 8 (53 %) 0.9
NEC 1 (7 %) 1 (7 %) 1 (7 %) 0 0.5
Treated ductus arteriosus 5 (33 %) 10 (67 %) 7 (47 %) 4 (27 %) 0.1
Intraventricular haemorrhage 5 (33 %) 3 (20 %) 4 (27 %) 1 (7 %) 0.5
Late onset sepsis 1 (7 %) 4 (27 %) 4 27(%) 5 (33 %) 0.3
Nasal trauma 1 (7 %) 1 (7 %) 0 (0 %) 1 (7 %) 0.4
Corrected gestation 30.3 30.6 32.1 30.0 0.3
(29.4, 33.0) (29.4, 32.1) (29.9, 34.7) (27.9, 32.6)
Mean weight - g (sd) 1218 (170) 1253 (294) 1342 (312) 1139 (318) 0.3
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significantly different. No infant was diagnosed with peri-
ventricular leucomalacia or had a PDA ligation.
Combined groups: HFNC versus no HFNC
No significant difference was found in primary outcomes
between infants receiving HFNC versus no HFNC
(Table 3). Infants allocated HFNC had a significant re-
duction in duration of NCPAP (median 12 days versus
24 days; p = 0.009). There were no significant differences
in days of pressure support, cGA off pressure support,
cGA off respiratory support, cGA at full suck feeds and
cGA at hospital discharge.
Combined groups: abrupt wean versus gradual wean
No significant difference in primary outcomes was found
between infants allocated abrupt wean versus gradual
wean (Table 4). Infants allocated abrupt wean had a sig-
nificant reduction in duration of HFNC (median 15 days
versus 30 days; p = 0.003). There were no significant
differences in other secondary outcomes at the pre-
specified level (p ≤ 0.01). However, infants allocated
abrupt wean had fewer days NCPAP (10.5 days versus
16.5 days; p = 0.02), reduced cGA off NCPAP (33.1 weeks
versus 34.6 weeks; p = 0.05), and fewer days pressure sup-
port (21.5 days versus 27.5 days; p = 0.04).
Discussion
This study was a pilot designed to determine the optimal
comparisons for a larger trial. None of the strategies re-
sulted in a significant effect on the prespecified primary
outcomes including incidence of CLD, duration of re-
spiratory support, days to full suck feeds or hospital stay
although the study is underpowered to find a difference.
However, there were significant differences between
groups in days of NCPAP and infants withdrawn from
treatment due to parental concern. The group abruptly
Table 2 Infant outcomes of four groups (data from randomisation; n (%) or median (IQR) unless specified)
Group 1 Group 2 Group 3 Group 4 ANOVA
n = 15 n = 15 n = 15 n = 15 p-value
CLD at 36 weeks 3 (20 %) 4 (27 %) 7 (47 %) 2 (13 %) 0.2
Days respiratory support 21 (9, 33) 26 (20, 38) 30 (24, 33) 24 (10, 35) 0.4
Days hospital stay 50 (39, 58) 53 (41, 71) 64 (50, 78) 53 (48, 66) 0.2
Days to full suck feeds 40 (35, 54) 51 (36, 66) 57 (41, 73) 51 (37, 64) 0.5
Days NCPAP 1 (0, 12) 24 (9, 28) 15 (11, 21) 24 (10, 35) 0.002
Gestational age off NCPAP 31.6 33.9 35.7 34.6 0.04
(30.0, 34.1) (32.1, 35.9) (31.0, 37.6) (31.9, 35.3)
Days HFNC from start of treatment 15 (7, 24) 30 (20, 34) 0.004
Days pressure support 15 (9, 29) 24 (9, 28) 30 (24, 33) 24 (10, 35) 0.1
Gestational age off pressure support 34.0 33.9 35.9 34.6 0.07
(32.7, 35.3) (32.1, 35.9) (33.9, 38.9) (31.9, 35.3)
Gestational age off respiratory support 34.7 34.1 35.9 34.6 0.1
(33.4, 35.3) (33.1, 36.0) (33.9, 38.9) (31.9, 35.3)
Gestational age at full suck feeds 36.9 37.1 39.6 37.3 0.1
(36.4, 38.0) (36.1, 40.6) (37.1, 44.0) (36.6, 39.1)
Gestation at discharge 37.7 37.9 39.9 38.3 0.1
(36.9, 39.1) (37.1, 40.1) (37.9, 45.0) (36.9, 39.7)
Postnatal growth failure 9 (60 %) 9 (60 %) 7 (47 %) 7 (47 %) 0.8
Weight at 36 weeks - g (sd) 2158 (411) 2044 (390) 2042 (338) 2128 (532) 0.4
Days caffeine 24 (24) 34 (30) 40 (22) 39 (33) 0.2
Grade 2 apnea (required IPPV) 0 1 (7 %) 0 0 0.4
Necrotising enterocolitis 0 1 (7 %) 0 0 0.4
Treated ductus arteriosus 2 (13 %) 5 (33 %) 4 (27 %) 1 (7 %) 0.2
Retinopathy of prematurity 7 (47 %) 6 (40 %) 6 (40 %) 6 (40 %) 0.6
Laser therapy 1 (7 %) 0 0 1 (7 %) 0.6
Nasal injury 0 0 1 (7 %) 1 (7 %) 0.4
Withdrawn 0 6 (40 %) 1 (7 %) 0 0.01
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weaning infants to HFNC had the shortest duration of
NCPAP. The group abruptly weaned without use of
HFNC had the highest withdrawal rate. In combined
group analysis, infants on HFNC had a significant reduc-
tion in days NCPAP. Use of HFNC may be an efficient
method for weaning infants from NCPAP even though it
did not reduce the overall duration of respiratory sup-
port, days to full suck feeds or duration of hospital stay.
In combined group analysis, abruptly weaning infants re-
duced the duration of HFNC required. This suggests the
best strategy for weaning infants from NCPAP is to
place them on HFNC when they are at a predefined level
of pressure support. Although abrupt weaning was also
associated with a reduced duration of NCPAP, corrected
gestational age off NCPAP and duration of pressure sup-
port, this did not reach our predefined significance level
for secondary outcomes.
HFNC delivers continuous distending pressure [16].
The delivered continuous distending pressure is higher
in smaller infants (<1500 g) [17], at higher flow rates
[17–20], using prongs with a larger outer diameter [19],
and when the infant’s mouth is closed [19]. Previous re-
search that assessed use of HFNC in preterm infants for
weaning from NCPAP reported use of HFNC was asso-
ciated with an increased exposure to oxygen and longer
duration of respiratory support. [15] However, in that
study HFNC flow used prongs with an outer diameter of
0.3 cm and flow was restricted to 2 L per minute. In
Table 4 Outcomes of combined abrupt versus gradual NCPAP wean groups (data from randomisation; n (%) or median (IQR) unless
specified)
Abrupt NCPAP wean Gradual NCPAP wean p-value
n = 30 n = 30
CLD at 36 weeks 7 (23 %) 9 (30 %) 0.6
Days respiratory support 24 (13, 34) 28 (17, 34) 0.4
Days hospital stay 52 (41, 63) 61 (48, 69) 0.1
Days to full suck feeds 46.5 (35, 58) 54.5 (41, 65) 0.2
Days NCPAP 11 (1, 26) 17 (10, 29) 0.02
Gestational age off NCPAP 33.1 (31.0, 34.6) 34.6 (31.8, 36.1) 0.05
Days HFNC from start of treatment 15 (7, 24) 30 (20, 34) 0.003
Days pressure support 22 (9, 28) 28 (17, 34) 0.04
Gestational age off pressure support 33.9 (32.6, 35.4) 34.9 (32.7, 36.7) 0.2
Gestational age off respiratory support 34.4 (33.1, 35.9) 34.9 (32.7, 36.7) 0.7
Gestational age at full suck feeds 37.1 (36.4, 39.1) 38.7 (36.8, 39.9) 0.1
Gestational age at discharge 37.8 (37.1, 39.4) 38.7 (37.4, 41.0) 0.2
Table 3 Outcomes of combined HFNC groups versus no HFNC groups (data from randomisation; n (%) or median (IQR) unless
otherwise specified)
HFNC No HFNC p-value
n = 30 n = 30
CLD at 36 weeks 10 (33 %) 6 (20 %) 0.2
Days respiratory support 28 (10, 36) 24 (16, 33) 0.7
Days hospital stay 56 (42, 67) 53 (46, 68) 0.7
Days to full suck feeds 47 (36, 65) 51 (39, 62) 0.5
Days NCPAP 12 (10, 33) 24 (1, 17) 0.009
Gestational age off NCPAP 33.0 (32.1, 35.4) 33.9 (30.9, 35.7) 0.4
Days HFNC from start of treatment 24 (11, 32) *
Days pressure support 27 (10, 33) 24 (15, 33) 0.3
Gestational age off pressure support 34.9 (32.1, 35.4) 33.9 (33.4, 36.8) 0.09
Gestational age off respiratory support 35.0 (32.5, 35.6) 34.4 (33.5, 36.8) 0.1
Gestational age at full suck feeds 37.6 (36.4, 39.2) 37.3 (36.7, 39.9) 0.5
Gestational age at discharge 38.4 (37.1, 39.7) 38.1 (37.3, 41.4) 0.3
* not applicable
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addition, infants were weaned from NCPAP when on a
relatively high fraction inspired oxygen (≤0.3) suggesting
the infants had more severe lung disease and were on a
higher level of respiratory support. In contrast, our study
weaned infants on NCPAP at 5cmH2O, the majority of
whom were in air, and used HFNC with an outer diam-
eter of 0.2 cm and commenced at 6 L/min. The effi-
ciency of HFNC in this study may be due to the use of
higher flow rates for weaning infants from lower levels
of respiratory support.
Two recent trials comparing use of HFNC versus
NCPAP for facilitating extubation in preterm infants re-
port similar efficacy for prevention of extubation failure
[12, 13] and reduced nasal trauma with HFNC [14]. It is
noteworthy that these trials did not report routine
mouth closure techniques for infants allocated NCPAP.
Mouth open is associated with loss of pharyngeal pres-
sure support and potentially efficacy of NCPAP [21]. A
third trial comparing HFNC versus NCPAP applied im-
mediately post extubation or early as initial non-invasive
support for respiratory dysfunction, reported similar effi-
cacy including no difference in early failure or need for
intubation [22]. Infants on HFNC had an increased dur-
ation of pressure support although there was no differ-
ence in duration of oxygen, bronchopulmonary dysplasia
or duration of hospitalisation. These trials and the
current study suggest HFNC has similar efficacy to
NCPAP for infants in need of lower levels of respiratory
support. A previous trial that assessed a practice of
abrupt weaning versus gradual weaning from NCPAP
when infants met prespecified stability criteria, reported
that abrupt weaning from NCPAP was associated with a
shorter duration of oxygen and time on respiratory sup-
port. [7] However, the trial had substantial differences in
baseline characteristics including gender and condition
at birth suggesting the results should be treated with
caution. Our trial had a similar set of ‘stability’ and ‘fail-
ure’ criteria. However, abrupt weaning without HFNC
was associated with a significantly increased rate of par-
ental withdrawal and no significant benefits. The reason
for withdrawal of all infants was dissatisfaction with
weaning method. Parents reported feeling their infant
was ‘failing the weaning process’ when attempting to
abruptly cease NCPAP. The analyses from our trial sug-
gest a strategy of abrupt wean with use of HFNC may be
the most efficient and acceptable to parents. Given this
is a small pilot study caution is advised in interpreting
the findings.
Given HFNC has been demonstrated to reduce nasal
trauma [14, 22], a trial of abrupt weaning of NCPAP
with HFNC versus gradual weaning of NCPAP may be
difficult to justify for infants on lower level respiratory
support. Further research is required to further define
the role of HFNC for primary respiratory support of
newborn infants and infants being extubated from
mechanical ventilation.
Conclusion
Use of high flow nasal cannula was effective at weaning
infants from NCPAP. Further trials are required to de-
termine if use of HFNC for weaning can reduce the dur-
ation of pressure support or reduce time to full suck
feeds. A strategy of weaning NCPAP to a predefined
level and then stopping NCPAP completely without use
of high flow nasal cannula was associated with increased
rate of withdrawal at parent request so may not be ac-
ceptable in all settings.
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